Trial Profile
Phase II, Open-Label, Single Arm Study of the Efficacy and Safety of X-396 Capsule in Patients With ROS1 Positive Advanced NSCLC
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 02 Dec 2021
Price :
$35
*
At a glance
- Drugs Ensartinib (Primary)
- Indications Adenocarcinoma; Brain metastases; Non-small cell lung cancer; Squamous cell cancer
- Focus Therapeutic Use
- Sponsors Betta Pharmaceuticals Co Ltd
- 12 Jul 2021 Primary endpoint (Objective response rate (ORR) based on independent radiology review (IRC) has not been met according to the results published in the Journal of Thoracic Oncology
- 12 Jul 2021 Status changed from recruiting to completed.
- 12 Jul 2021 Results assessing efficacy and safety of ensartinib in the treatment of patients with ROS1-positive NSCLC published in the Journal of Thoracic Oncology